Shelton Capital Management reduced its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 76.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,012 shares of the life sciences company's stock after selling 20,049 shares during the period. Shelton Capital Management's holdings in Illumina were worth $803,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Golden State Wealth Management LLC bought a new position in shares of Illumina during the 4th quarter valued at $32,000. Versant Capital Management Inc lifted its position in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after buying an additional 146 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Illumina during the 4th quarter valued at about $45,000. Assetmark Inc. raised its stake in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after acquiring an additional 296 shares in the last quarter. Finally, Lee Danner & Bass Inc. acquired a new position in Illumina during the fourth quarter valued at approximately $48,000. 89.42% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on ILMN. Canaccord Genuity Group lowered their price target on Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a research report on Tuesday, March 11th. Piper Sandler raised their price target on shares of Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Citigroup decreased their target price on Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. Royal Bank of Canada decreased their price objective on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 8th. Finally, HSBC downgraded Illumina from a "buy" rating to a "hold" rating and set a $100.00 target price on the stock. in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $138.70.
Check Out Our Latest Report on ILMN
Illumina Stock Performance
Shares of ILMN stock traded down $0.33 on Tuesday, hitting $74.73. The company's stock had a trading volume of 291,652 shares, compared to its average volume of 2,262,910. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The stock's 50 day moving average is $87.59 and its 200-day moving average is $121.87. The company has a market capitalization of $11.84 billion, a PE ratio of -9.73, a PEG ratio of 1.60 and a beta of 1.38.
Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.
Illumina Profile
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Further Reading
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
